Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

PURPOSE: Current knowledge of the reasons for patients’ preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences. PATIENTS AND METHODS: In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C, Betteridge, Neil, Brown, T Michelle, Woolcott, John, Kivitz, Alan J, Zerbini, Cristiano, Whalley, Diane, Olayinka-Amao, Oyebimpe, Chen, Connie, Dahl, Palle, Ponce de Leon, Dario, Gruben, David, Fallon, Lara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980841/
https://www.ncbi.nlm.nih.gov/pubmed/32021123
http://dx.doi.org/10.2147/PPA.S220714
_version_ 1783491001505021952
author Taylor, Peter C
Betteridge, Neil
Brown, T Michelle
Woolcott, John
Kivitz, Alan J
Zerbini, Cristiano
Whalley, Diane
Olayinka-Amao, Oyebimpe
Chen, Connie
Dahl, Palle
Ponce de Leon, Dario
Gruben, David
Fallon, Lara
author_facet Taylor, Peter C
Betteridge, Neil
Brown, T Michelle
Woolcott, John
Kivitz, Alan J
Zerbini, Cristiano
Whalley, Diane
Olayinka-Amao, Oyebimpe
Chen, Connie
Dahl, Palle
Ponce de Leon, Dario
Gruben, David
Fallon, Lara
author_sort Taylor, Peter C
collection PubMed
description PURPOSE: Current knowledge of the reasons for patients’ preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences. PATIENTS AND METHODS: In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients’ strength of preference was evaluated using a 100-point allocation task (0–100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences. RESULTS: 100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a “strong” first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively. CONCLUSION: These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making.
format Online
Article
Text
id pubmed-6980841
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69808412020-02-04 Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making Taylor, Peter C Betteridge, Neil Brown, T Michelle Woolcott, John Kivitz, Alan J Zerbini, Cristiano Whalley, Diane Olayinka-Amao, Oyebimpe Chen, Connie Dahl, Palle Ponce de Leon, Dario Gruben, David Fallon, Lara Patient Prefer Adherence Original Research PURPOSE: Current knowledge of the reasons for patients’ preference for rheumatoid arthritis (RA) treatment modes is limited. This study was designed to identify preferences for four treatment modes, and to obtain in-depth information on the reasons for these preferences. PATIENTS AND METHODS: In this multi-national, cross-sectional, qualitative study, in-depth interviews were conducted with adult patients with RA in the United States, France, Germany, Italy, Spain, Switzerland, the United Kingdom, and Brazil. Patients’ strength of preference was evaluated using a 100-point allocation task (0–100; 100=strongest) across four treatment modes: oral, self-injection, clinic-injection, and infusion. Qualitative descriptive analysis methods were used to identify, characterize, and summarize patterns found in the interview data relating to reasons for these preferences. RESULTS: 100 patients were interviewed (female, 75.0%; mean age, 53.9 years; mean 11.6 years since diagnosis). Among the four treatment modes, oral administration was allocated the highest mean (standard deviation) preference points (47.3 [33.1]) and was ranked first choice by the greatest percentage of patients (57.0%), followed by self-injection (29.7 [27.7]; 29.0%), infusion (15.4 [24.6]; 16.0%), and clinic-injection (7.5 [14.1]; 2.0%). Overall, 56.0% of patients had a “strong” first-choice preference (ie, point allocation ≥70); most of these patients chose oral (62.5%) vs self-injection (23.2%), infusion (10.7%), or clinic-injection (3.6%). Speed and/or ease of administration were the most commonly reported reasons for patients choosing oral (52.6%) or self-injection (55.2%). The most common reasons for patients not choosing oral or self-injection were not wanting to take another pill (37.2%) and avoiding pain due to needles (46.5%), respectively. CONCLUSION: These data report factors important to patients regarding preferences for RA treatment modes. Patients may benefit from discussions with their healthcare professionals and/or patient support groups, regarding RA treatment modes, to facilitate shared decision-making. Dove 2020-01-20 /pmc/articles/PMC6980841/ /pubmed/32021123 http://dx.doi.org/10.2147/PPA.S220714 Text en © 2020 Taylor et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Taylor, Peter C
Betteridge, Neil
Brown, T Michelle
Woolcott, John
Kivitz, Alan J
Zerbini, Cristiano
Whalley, Diane
Olayinka-Amao, Oyebimpe
Chen, Connie
Dahl, Palle
Ponce de Leon, Dario
Gruben, David
Fallon, Lara
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
title Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
title_full Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
title_fullStr Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
title_full_unstemmed Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
title_short Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
title_sort treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980841/
https://www.ncbi.nlm.nih.gov/pubmed/32021123
http://dx.doi.org/10.2147/PPA.S220714
work_keys_str_mv AT taylorpeterc treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT betteridgeneil treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT browntmichelle treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT woolcottjohn treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT kivitzalanj treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT zerbinicristiano treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT whalleydiane treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT olayinkaamaooyebimpe treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT chenconnie treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT dahlpalle treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT poncedeleondario treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT grubendavid treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking
AT fallonlara treatmentmodepreferencesinrheumatoidarthritismovingtowardshareddecisionmaking